NCT04333771View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

566

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

January 30, 2023

Study Completion Date

September 21, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

SHR0302

The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.

DRUG

Placebo

The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.

Trial Locations (1)

Unknown

Liuzhou workers' Hospital, Liuzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04333771 - A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter